Arca
Skip to content
Tools
Tools

Relapsing-remitting multiple sclerosis

Drug research and approvals for relapsing-remitting multiple sclerosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 56 studies of relapsing-remitting multiple sclerosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, FDA has 4 approved and 0 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 56
  • Trials authorized in Canada: 11
  • FDA orphan approvals: 4
  • EU medicines: 2

Recruiting now

Newest posted first, of 56 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 12

Phase 3 12 of 29

Phase 2 12 of 36

Phase 1 or earlier 12 of 18

How its trials ended

563 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 187 whose ending is known, 47% met their primary endpoint, 9% missed it and 45% stopped early.

  • Completed, result not reported23241%
  • Ongoing9517%
  • Met its primary endpoint8715%
  • Status unknown499%
  • Stopped: other or unclear407%
  • Stopped: enrollment or feasibility193%
  • Missed its primary endpoint163%
  • Stopped: sponsor or business decision132%
  • Stopped: lack of efficacy81%
  • Stopped: funding41%

Trials authorized in Canada

The 10 newest of 11; search them all in Canada trials
Nov 29, 2024A randomized, double-blind, parallel-group study to compare pharmacokinetics, pharmacodynamics, clinical effects, and safety between abp 692 and ocrevus®…Abp 692AmgenOngoing
Dec 29, 2021A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with…Remibrutinib (LOU064) / TeriflunomideNovartis PharmaceuticalsOngoing
Oct 15, 2018An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing…Ofatumumab (OMB157)Novartis PharmaceuticalsOngoing
Oct 11, 2018A randomized, controlled, open-label, rater-blinded, phase 3b study of the efficacy, safety, and tolerability of 6-week extended interval dosing of natalizumab…Tysabri (natalizumab)BiogenClosed
Jan 26, 2017An open-label, single-arm study to evaluate the effectiveness and safety of ocrelizumab in patients with early stage relapsing remitting multiple sclerosisRO4964913 (ocrelizumab)RocheOngoing
Dec 16, 2016A phase 3b, 12-month, open-label, multicenter study to evaluate the efficacy and safety of BIIB019, daclizumab, in subjects with relapsing-remitting multiple…DaclizumabBiogenOngoing
Mar 30, 2016A phase 3 open label study to evaluate the long-term safety and tolerability of alks 8700 in adults with relapsing remitting multiple sclerosisAlks 8700AlkermesClosed
Oct 8, 2015An open-label study to assess the effects of BG00012 on lymphocyte subsets in subjects with relapsing-remitting multiple sclerosisTecfidera (dimethyl fumarate, BG00012)BiogenClosed
Aug 5, 2015Open-label, randomized, multicenter, multiple-dose, active-controlled, parallel-group, efficacy and safety study of BG00012 in children from 10 to less than 18…Dimethyl fumarate/ Interferon BETA-1ABiogenClosed
Mar 4, 2015Randomized, controlled pilot trial of domperidone in relapsing-remitting multiple sclerosis (MS)DomperidoneUniversity of CalgaryClosed

FDA orphan designations

Approved first, then open designations, newest first
Oct 13, 2000NovantroneReducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive…Serono, Inc.Approved
Oct 13, 2000NovantroneReducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive…Serono, Inc.Approved
Dec 20, 1996CopaxoneFor reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.Teva Pharmaceuticals USAApproved
Jul 23, 1993BetaseronIn ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations.Chiron Corp. & Berlex LaboratoriesApproved

Medicines authorised in the EU

Newest first
May 20, 2020ZeposiaOzanimodBristol-Myers Squibb Pharma EEIGEMA ↗
Sep 12, 2013LemtradaAlemtuzumabSanofi BelgiumEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.